Twill's Director of Clinical Operations provides an in-depth look into the DTx industry, addressing questions such as:
- Is a defined bar of validation set for digital therapeutic clinical trials?
- Should FDA and non-FDA regulated digital therapeutics require different levels of validation or should it be uniform?
- What are the current requirements for DTx clinical trials to be considered successful?
